TY - BOOK ID - 135420187 TI - Radiation Response Biomarkers for Individualised Cancer Treatments AU - Badie, Christophe AU - Rutten, Eric Andreas PY - 2021 PB - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - carbon-ion radiotherapy KW - head-and-neck tumors KW - squamous cell carcinoma KW - radiosensitivity KW - relative biological effectiveness KW - lung cancer KW - radiotherapy KW - radiotherapy monitoring KW - radiation-induced lung injury KW - RILI KW - pneumonitis KW - radiation-induced lung fibrosis KW - RILF KW - circulating biomarkers KW - microRNA KW - micronuclei KW - uterine cervical cancer KW - cGAS KW - STING KW - abscopal effect KW - immunotherapy KW - PBMCS KW - micronucleus assay KW - biological dosimetry KW - human blood KW - genotoxicity tests KW - ionizing radiation KW - biomarkers KW - dicentric assay KW - gamma H2AX foci assay KW - health surveillance analyses KW - clonogenic assays KW - methods KW - plating KW - cancer KW - radiation KW - head and neck cancer KW - exosomes KW - serum KW - metabolomics KW - GC/MS KW - biodosimetry KW - chromosome aberrations KW - normal tissue toxicity KW - predictive tests KW - normal tissue KW - biomarker KW - protein KW - immune infiltrate KW - stroma KW - tumour microenvironment KW - proteomics KW - telomeres KW - chromosomal instability KW - inversions KW - prostate cancer KW - IMRT KW - machine learning KW - individual radiosensitivity KW - late effects KW - personalized medicine KW - liquid biopsy KW - circulating tumour cells KW - extracellular vesicles KW - microRNAs KW - immune system KW - inflammation KW - n/a UR - https://www.unicat.be/uniCat?func=search&query=sysid:135420187 AB - Personalised medicine is the next step in healthcare, especially when applied to genetically diverse diseases such as cancers. Naturally, a host of methods need to evolve alongside this, in order to allow the practice and implementation of individual treatment regimens. One of the major tasks for the development of personalised treatment of cancer is the identification and validation of a comprehensive, robust, and reliable panel of biomarkers that guide the clinicians to provide the best treatment to patients. This is indeed important with regards to radiotherapy; not only do biomarkers allow for the assessment of treatability, tumour response, and the radiosensitivity of healthy tissue of the treated patient. Furthermore, biomarkers should allow for the evaluation of the risks of developing adverse late effects as a result of radiotherapy such as second cancers and non-cancer effects, for example cardiovascular injury and cataract formation. Knowledge of all of these factors would allow for the development of a tailored radiation therapy regime. This Special Issue of the Journal of Personalised Medicine covers the topic of Radiation Response Biomarkers in the context of individualised cancer treatments, and offers an insight into some of the further evolution of radiation response biomarkers, their usefulness in guiding clinicians, and their application in radiation therapy. ER -